Safe Harbor Fiduciary LLC Buys Shares of 500 Amgen Inc. (NASDAQ:AMGN)

Safe Harbor Fiduciary LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 500 shares of the medical research company’s stock, valued at approximately $130,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ascent Wealth Partners LLC boosted its position in shares of Amgen by 0.7% during the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company’s stock worth $2,352,000 after buying an additional 64 shares during the period. ICICI Prudential Asset Management Co Ltd raised its holdings in Amgen by 242.2% during the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company’s stock worth $6,255,000 after purchasing an additional 16,985 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Amgen by 285.4% during the fourth quarter. Fisher Asset Management LLC now owns 394,489 shares of the medical research company’s stock worth $102,820,000 after purchasing an additional 292,137 shares in the last quarter. Aire Advisors LLC raised its holdings in Amgen by 26.3% during the fourth quarter. Aire Advisors LLC now owns 13,280 shares of the medical research company’s stock worth $3,461,000 after purchasing an additional 2,762 shares in the last quarter. Finally, Beacon Harbor Wealth Advisors Inc. bought a new stake in Amgen during the fourth quarter worth approximately $3,531,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Up 0.3%

Shares of AMGN opened at $272.41 on Friday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market cap of $146.48 billion, a P/E ratio of 36.08, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The firm’s 50-day simple moving average is $291.00 and its 200 day simple moving average is $288.28. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.96 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s payout ratio is 86.86%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent analyst reports. Johnson Rice set a $294.00 target price on Amgen in a report on Wednesday, March 5th. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 10th. Citigroup reissued a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Morgan Stanley reiterated an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $310.18.

Insider Activity at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.76% of the stock is owned by insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.